Mifepristone (RU486): Designing Better Assays
2026-09-25
Mifepristone (RU486) is a progesterone receptor antagonist used to probe reproductive and tumor biology. This guide connects its established experimental applications with an integrated assay-design framework, while clarifying what cardiomyocyte screening evidence can—and cannot—tell researchers.
MnO₂–Ca²⁺ Hydrogel for Diabetic Wound Repair
2026-09-24
The study presents a dynamically responsive PVA/HAMA hydrogel that combines MnO₂ nanozymes, SDS-C18 micelles, and calcium-ion regulation to address several features of diabetic wounds. In vitro assays and a diabetic-mouse wound model indicate antioxidant and antibacterial activity, enhanced cell migration, and substantial wound closure, while leaving important questions about mechanism, durability, and clinical translation for future work.
BMX Kinase: From Lysosomal Control to Translation
2026-09-24
New evidence connects BMX kinase to lysosomal acidification and Mycobacterium tuberculosis survival, broadening the questions researchers can ask with selective chemical inhibition. Learn how BMX-IN-1 can support mechanistic studies across host-pathogen biology and cancer research—and how to design experiments that distinguish promising biology from translational proof.
Calcitriol Workflows for VDR Research
2026-09-23
Calcitriol enables controlled studies of vitamin D receptor signaling across decidualization, immune modulation, and cancer biology. This practical guide combines formulation advice, time-resolved assays, pathway-specific controls, and troubleshooting strategies for reproducible bench workflows.
Quinolone–Coumarin Hybrids Against T. gondii
2026-09-22
A 2024 Acta Parasitologica study evaluated quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii in vitro. Several candidates, together with novobiocin, reduced infection-associated readouts while showing more favorable selectivity than pyrimethamine, supporting further antiparasitic lead optimization rather than immediate clinical use.
SB 225002: From IL-8 Biology to Translational Insight
2026-09-22
A receptor-resolved framework for using SB 225002 to distinguish CXCR2-driven neutrophil trafficking from CXCR1-centered tumor signaling in emerging oral cancer and microbial extracellular-vesicle models.
MDL 28170: A Translational Calpain Inhibitor
2026-09-21
MDL 28170 offers a mechanistically grounded way to test whether excessive calpain activity drives synaptic, neuronal, and cognitive injury. This thought-leadership article translates evidence from a maternal surgery model into practical guidance for neuroprotection research, apoptosis assay design, and ischemia-reperfusion injury studies.
Cyclo (-RGDfC) in 96-Well Integrin Assays
2026-09-21
Cyclo (-RGDfC) combines cyclic RGD recognition with a practical DMSO-based workflow for αvβ3 integrin studies. Paired with open-platform digital light patterning, it enables more controlled comparisons of cell adhesion, migration, tumor targeting, and biomaterial geometry in plate-based experiments.
Angiotensin (1-7): Applied Research Workflows
2026-09-20
Use Angiotensin (1-7) as a defined Mas receptor probe for fibrosis, inflammation, metabolism, and peptide-processing studies. This guide connects controlled dosing with a periodontal RAS workflow that distinguishes direct peptide activity from Angiotensin I conversion.
Rifampin Workflows for Bacterial Transcription Studies
2026-09-19
Rifampin provides a practical chemical switch for probing bacterial transcription, resistance evolution, and synthetic gene circuits. This workflow-focused guide covers stock preparation, time-resolved assays, orthogonal validation, and troubleshooting for reliable rifamycin antibiotic experiments.
Naftifine HCl: From Sterol Biology to Translation
2026-09-19
A thought-leadership guide to using Naftifine HCl as a rigorous allylamine antifungal agent for sterol-biosynthesis research, while distinguishing its fungal mechanism from WNT5a/GSK3/β-catenin biology in muscle regeneration.
AR Heterogeneity Shapes Castration and Enzalutamide Response
2026-09-18
Li et al. show that prostate cancer cells with nuclear, mixed nuclear/cytoplasmic, or low/absent androgen receptor expression occupy biologically distinct states with different responses to castration and enzalutamide. By integrating patient tissue analysis, engineered cell clones, xenografts, RNA sequencing, and combination treatment experiments, the study identifies BCL-2 as a tractable vulnerability in both AR-high and AR-low castration-resistant disease.
SIRT1, Type H Vessels, and Bone Regeneration
2026-09-17
Liu et al. show that declining SIRT1 activity contributes to impaired vascular and osteogenic function in aged bone, while SIRT1 activation improves regeneration in femoral and mandibular defects. The study identifies β-catenin deacetylation and nuclear translocation as a mechanistic link between SIRT1 activity, Wnt signaling, endothelial behavior, and osteogenesis.
Cinoxacin BA1045 for Reproducible Bacterial Assays
2026-09-17
Learn how Cinoxacin (SKU BA1045) can improve interpretation of Gram-negative bacterial viability, susceptibility, and cytotoxicity workflows. This scenario-based guide covers assay design, formulation, concentration selection, controls, data interpretation, and practical product-selection criteria.
BI 2536: A Mechanistic PLK1 Probe
2026-09-17
BI 2536 is a selective PLK1 inhibitor that connects mitotic kinase activity with checkpoint-complex disassembly. This article develops a mechanism-first framework for interpreting G2/M arrest, apoptosis, and tumor xenograft data without treating every mitotic phenotype as equivalent.